Company Overview
Azevan Pharmaceuticals is a clinical stage, small molecule drug development company developing novel therapeutics to treat stress-related CNS disorders and neurodegenerative conditions. The Company’s first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of multiple disorders, including Intermittent Explosive Disorder, neuropsychiatric symptoms in neurodegenerative diseases, and PTSD. Vasopressin also is a key early signal in the neurological damage seen in traumatic brain injury and stroke. Vasopressin 1a receptor antagonists represent a novel mechanism of action for addressing these indications.